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A b s t r a c t  
The aim of present study was to enhance solubility of poorly soluble antimalarial drugs, Artemisinin 
and Curcumin by adopting Co-solvency approach and to develop parenteral aqueous injectable 
solution. Solubility enhancement of both drugs was achieved using co-solvency approach. The 
parenteral injection was prepared by using a ternaryco-solvent system which comprised of benzyl 
alcohol, PEG 400 and tween 80 (as surfactant). Solubility of Artemisinin and Curcumin was found to 
be higher in benzyl alcohol and PEG 400. Co-solvent system comprising of benzyl alcohol, PEG 400 
and tween 80 in volume fraction of 0.3, 0.9 and 0.2 respectively showed the minimum required 
solubility of Artemisinin (90 mg per ml) and Curcumin (180 mg per ml). The parenteral injectable 
formulation was characterized for pH, clarity, viscosity, osmolarity and sterility and the stated 
parameters were found in acceptable range.  In-vitro erythrocyte toxicity study showed that 
intravenous administration of optimized formulation will be safe. In-vitro antimalarial assay indicated 
that efficacy of artemisinin and curcumin parenteral formulation was greater than quinine and 
combination of Artemether and Lumefantrine. Stability study of the optimized batch showed no 
change in physical and chemical characteristics. Potential implications: Based on study, one can 
conclude that Artemisinin and Curcumin can be successfully formulated as parenteral injectable 
formulation by co-solvency approach for the effective treatment of malarial infection. 
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Introduction 
Malaria is caused by a parasite called plasmodium, which is 
transmitted via the bites of infected mosquitoes. In the human 
body, parasites multiply in the liver, and then infect red blood cells. 
The symptoms of malaria include fever, headache, and vomiting, 
and they usually appear between 10 and 15 days after the 
mosquito bite. If malaria is not treated, it can quickly become life-
threatening by disrupting the blood supply to the vital organs [1]. 
From the five species that infect humans, P. falciparum is the one 
responsible for majority of  the mortality and morbidity associated 
with malaria [2]. Malaria is curable if effective treatment is started 
early. Delay in treatment may lead to serious consequences 
including death. Burden of malaria in India is 180 million, with as 
many as 90 million cases of P. falciparum malaria per year. 
Malaria occurs during the blood-stage of the parasite’s life-cycle 
where the parasite is known to replicate exclusively within 
erythrocytes. Infected individuals can also suffer relapses years 
after P. vivax and P. ovale infections due to parasites surviving in 
hepatocytes [3]. Two classes of drugs are currently available for the 
treatment of severe malaria: the cinchona alkaloids– Quinine and 
the Artemisinin derivatives. 
The major problem with the currently available ant malarial drugs is 
that some malaria parasites have continuously developed 
resistance to these drugs [4]. Artemisinin (ART) derivatives have 
given efficacious result against malarial parasites. However, the 
requirement of a 7 day ART monotherapy has led to incomplete 
patient compliance and possible resistance development. As per 
the recommendation of World Health Organization (WHO), ART-
based 3-day combination therapy may enhance the efficacy of this 
treatment and delay development of resistance. However, there is 
a need to develop newer ART-based combination therapy [5]. 
Combination therapy of Artemisinin and Curcumin adds a new 
dimension to malaria therapy in terms of its potential to prevent 
parasite recrudescence and relapse in falciparum and vivax malaria 
as well as to protect against cerebral malaria [6]. 
Curcumin, a hydrophobic polyphenol extracted from the roots of 
Curcuma longa  L. is a staple of traditional Indian medicine 
including Ayurveda [7]. Recently a synergistic effect of Artemisinin 
and Curcumin against the malarial plasmodium, both in vitro and in 
vivo, has been proved. Curcumin is well tolerated even at very high 
doses and is a economical drug, hence its combination with 
Artemisinin may offer several advantages over conventional 
Artemisinin combination therapy, including a decreased Artemisinin 
dosage and reduced cost of therapy [8]. However, the poor water 
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solubility, incomplete absorption and poor bioavailability due to 
extensive first-pass metabolism of both compounds challenge their 
oral pharmaceutical formulations [9]. To resolve the issue of poor 
bioavailability and incomplete absorption, it is necessary to develop 
parenteral formulation with enhanced solubility of Artemisinin and 
Curcumin. Co-solvency, pH adjustment, surfactant addition, and 
complication are the most commonly used pharmaceutical 
approaches for solubilizing drug candidates with low aqueous 
solubility. Among them, use of co-solvent is one of the most 
popular approaches for improving the solubility of poorly aqueous 
soluble drugs in pharmaceutical liquid formulations. Addition of a 
co-solvent to a formulation improves the solubility of the drug by 
reducing strong water-water interactions and thereby reducing the 
ability of water to squeeze out non-polar solutes [10].In this study 
ethanol, glycerin, PEG-400 and propylene glycol were used as co-
solvents to enhance solubility of Artemisinin and Curcumin [11]. 
The objective of the present study has to prepare and evaluate the 
injectable dosage form of the two drugs. 
 
Materials and methods 
 
Materials 
 
Artemisinin was obtained from Arihantam Life Care, Vapi, India. 
Curcumin was obtained from Pharmanza (India) Pvt. Ltd, 
Khambhat, India. Ethanol, benzyl alcohol and propylene glycol 
were obtained from Atul Chemicals, Anand, India. Glycerine and 
PEG-400 were obtained from Astron Chemicals, Ahmadabad, 
India. Tween 80 was obtained from S.D. Fine Chemical Ltd. Boisar, 
India. 
 
Solubility of Artemisinin and Curcumin in individual 
solvents and binary system 
 
Screening of solvents was done on the basis of solubility of 
Artemisinin and Curcumin in various solvents such as ethanol, 
benzyl alcohol, glycerin, PEG-400 and propylene glycol. Solubility 
was determined by equilibrium solubility method [12]. Excess 
amount of Artemisinin and Curcumin were individually added to 
screw-capped glass vials containing 5ml of the solvent. The vials 
were shaken mechanically for 24 hours on a mechanical shaker 
(RIS-24BL, REMI) at 37 ± 2∘C. After 24 hours, the mixture was 
transferred into Eppendorf tubes and centrifuged at 6000 rpm for 
20 min. The supernatants were collected from each Eppendorf tube 
and analyzed for drug content, after appropriate dilutions by UV-
Visible spectrophotometer (Shimadzu, 1650 PC, Kyoto, Japan) at 
292nm and 470nm for Artemisinin and Curcumin respectively. The 
study was performed in triplicate. Table 1and Table 2 shows the 
solubility data of the drugs. 
 
Construction of ternary phase diagram  
Ternary phase diagram was constructed on the basis of 
measurement of refractive index of ternary solvent system [13]. 
Ternary solvent systems containing different composition of 
solvents were prepared and their refractive index was measured. 
Measured refractive index of solvent system was compared with 
refractive index of water. Ternary phase diagram was constructed 
by using Prosim software [14]. Figure 1 shows the ternary phase 
diagram. 
 
Preparation of parenteral injection 
  
On the basis of solubility data obtained from ternary solvent 
system, formulation of parenteral injection of Artemisinin and 
Curcumin was prepared using optimized solvent system. This 
formulation also contained permissible excipients such as the 
osmogen (4%) and antioxidant (0.1%). 
 
Drug-excipient compatibility studies 
  
UV spectral studies 
 
UV spectral study of Artemisinin and Curcumin was performed. UV 
spectra of both the drugs in different solvents was measured for 
change in wavelength  maxima [15]. The change in wavelength 
was considered as drug and excipient interaction. Figure 2 and 
Figure 3 shows the results. 
 
Fourier Transform Infrared Spectroscopy (FTIR) study 
 
The infra-red spectra of Artemisinin, Curcumin and co-solvent 
system having benzyl alcohol, PEG 400 and Tween 80 were 
recorded on Fourier Transform Infrared Spectrophotometer (Perkin 
Elmer – spectrum Bx, USA) in order to detect the existence of 
interaction between drug and solvents. The procedure consisted of 
uniformely dispersing a sample(10%w/w) in potassium bromide  
and finally compress it into pellets. The pellet was placed in light 
path and spectrum was recorded at a resolution of2 cm-1 over a 
frequency range of 4000 to 400 cm-1. The background spectrum of 
KBr was used as blank for determination. 
 
Differential scanning calorimetric study 
 
Differential scanning calorimeter (DSC) was used (Perkin Elmer 
DSC-7, Norway, USA.) to study the thermal behavior of 
Artemisinin, Curcumin and co-solvent system comprising of benzyl 
alcohol, PEG 400 and Tween 80. The instrument comprised of 
calorimeter (DSC-60), flow controller (FCL-60), thermal analyzer 
(TA-60) and operating software (TA-60). The samples (2-4 ml) 
were heated in hermetically sealed flat-bottomed aluminum pans 
under nitrogen flow (20ml/min) at a scanning rate of 10∘C/min from 
Thakkar et al. International Journal of Drug Delivery 8 (3) 77-88 [2016] 
 
 
  
PAGE | 79 | 
 
 
25∘C to 340∘C.  Empty aluminum pans were used as the reference 
standard. 
 
Characterization of aqueous injection containing 
Curcumin and Artemisinin 
 
pH, clarity, viscosity, surface tension and specific 
gravity 
 
The pH of prepared aqueous injection was measured employing a 
pH meter (Lab India Pico+ Japan). The parenteral formulation was 
inspected against black and white background to assess presence 
of particulate matters. Viscosity, surface tension and specific 
gravity of the aqueous injection were measured using an Ostwald 
viscometer, Stalagmometer and relative density bottle method 
respectively. The measurements were performed in triplicate and 
the mean parameters of the aqueous injection were calculated.  
 
Drug content estimation  
 
Ratio derivative first order method was adopted for simultaneous 
estimation of Artemisinin and Curcumin in an aqueous injection. 
The data of zero order spectra for both drugs were divided by 
optimized divisor concentration. The ratio spectra of each solution 
were obtained and converted into first derivative. The converted 
ratio first derivative spectra were obtained at 293.17 nm and 457 
nm for detection of Artemisinin and Curcumin respectively. 
 
Osmolarity 
 
The osmolarity of prepared co-solvent systems was determined 
with a vapor pressure osmometer (Supratech Laboratory, 
Ahmedabad). 
 
Leaching/extraction from the test container 
 
It was carried out by filling prepared aqueous injection in different 
container like glass vial, amber colour glass ampoule and flint glass 
ampoule. The containers were incubated for 15 days at ambient 
storage condition and the effect on pH, viscosity and  drug content 
of formulation was measured [16]. 
 
In-vitro erythrocyte toxicity study 
 
The In-vitro erythrocyte toxicity study was conducted for estimating 
the damage to the membrane which may be caused by formulation 
components [17]. Blood sample was collected in the vial containing 
EDTA (anticoagulant). Red blood cells (RBCs) were isolated by 
centrifugation (5,000 rpm for 5 min) and the RBCs were washed 
three times with isotonic phosphate buffer pH 7.4 before diluting 
with buffer to prepare erythrocyte stock dispersion (three parts of 
centrifuged erythrocytes plus eleven parts buffer). The buffer 
consisted of Na2PO4·10H2O (7.95 g), KH2PO4(0.76 g), NaCl (7.2 
g), and distilled water (q.s to 1000 ml). The washing step was 
repeated in order to remove debris and serum protein. A 100 
microlitres aliquot stock dispersion was added per milliliter of test 
samples. The resulting solution was incubated at 37°C for a period 
of 1 h. After incubation under shaking, debris and intact 
erythrocytes were removed by centrifugation. One hundred 
microliters of resulting supernatant was added to 2 ml of an 
ethanol/HCl mixture [(39 parts ethanol (99% v/v) + 1 part of HCl 
(37% w/v)]. This mixture dissolved all components and avoided the 
precipitation of hemoglobin [18]. The absorbance of the mixture 
was determined at 398 nm by spectrometer monitoring against a 
blank sample. Control sample of 100% lyses (in TritonX100) was 
employed in the experiment [19]. The percentage of haemolysis 
caused by the test sample was calculated by following equation: 
Haemolysis caused by sample (%) = (Absorbance of test sample/ 
Absorbance  at 100% lyses)*100 
 
In-vitro anti-malarial assay 
 
The test concentration which inhibits the complete maturation of ring 
stage parasites into schizonts was recorded as the minimum 
inhibitory concentration(MIC) [20]. It was carried out at Microcare 
Laboratory, Seurat. The injection of Artemisinin and Curcumin was 
taken as test sample and MIC was recorded and results were 
compared with Quinine (reference drug) and marketed combination 
of Artemether and Lumefantrine.  
The in-vitro ant malarial assay was carried out in 96 well microstate 
plates according to the micro assay protocol of Reichmann et al. 
1978 [21]. The cultures of P. falciparum strain were maintained in 
medium RPMI-1640 supplemented with 25mM HEPES, 1%D-
glucose, 0.23% sodium bicarbonate and 10% heat inactivated 
human serum. The synchronous parasites of P. falciparum were 
synchronized after 5% D-sorbitol treatment to obtain only the ring 
stage parasitized cells. For carrying out the assay, an initial ring 
stage parasitaemiaof0.8to1.5% at 3% haematocrit in a total volume 
of 200µl of medium RPMI-1640 was determined by Jaswant Singh 
Bhattacharya (JSB) staining to assess the percent parasitaemia 
(rings) and uniform molly maintained with 50% RBCs (O+) [22]. A 
stock solution of 5mg/ml of each of the test samples was mixed with 
culture medium. The diluted samples in 20 µl volume were added to 
the test wells so as to obtain final concentrations (at fivefold 
dilutions) ranging between 0.4 µg/ml to 100 µg/ml in duplicate well 
containing parasitized cell preparation. The culture plates were 
incubated at 37oC in a candle jar. After 36 to 40h incubation, thin 
blood smears from each well were prepared and stained with JSB 
stain. The slides were microscopically observed to record 
maturation of ring stage parasites. 
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Sterility testing 
Sterility testing was carried out by incubating formulations for seven 
days at 32.5±2.5ºC in the alternative thioglycolate medium(ATGM) 
to find the growth of bacteria and at 22.5 ± 2.5º C in soya bean-
casein digest medium(SCDM) to find the growth of fungi in the 
formulation. 
 
Stability study 
 
The sealed vials of the aqueous injections were inspected every 
day for 30 days for color, turbidity and pH of the formulation. The 
chemical stability of the formulation was assessed by the 
estimation of the percentage drug remaining in the formulation on 
storage at 2–8 ºC in a refrigerator, room temperature, and 40 
ºC/75% RH in humidity chamber (Zebra instrument and equipments 
company-Ahmadabad) at 0, 15 and 30 days interval. 
Results and Discussion 
 
Solubility of Artemisinin and Curcumin in individual 
solvents 
 
The selected solvents have lower polarity as compared to water 
and are cleared for use in parenterals. The solubility of Artemisinin 
and Curcumin in different solvents at 25°C was studied and 
solubility data are shown in Table 1. The enhancement factor 
varied and the maximum observed was 42600. The enhancement 
factor was inversely related with solvent polarity. The selected 
solvents showed higher solubility as compared to water. Ethanol, 
PEG-400 and benzyl alcohol were found to be better solvents in 
case of Artemisinin and Curcumin. 
Table 1: Artemisinin and Curcumin solubility and enhancement factor in various solvents at 25° C 
 
 
Solvent 
Artemisinin Curcumin 
Solubility ± S.D. 
(mg/ml) 
Enhancement Factor* Solubility ± S.D. 
(mg/ml) 
Enhancement Factor 
Water 0.07 ± 0.0011 1 0.01 ± 0.0057 1 
Glycerine 0.083 ± 0.0005 1.18 0.05 ± 0.0057 5 
Propylene Glycol  2.03 ± 0.0115 29.00 3.22 ± 0.01155 322 
Ethanol 3.20 ± 0.010 45.71 4.12 ± 0.010 412 
PEG-400 10.22 ± 0.0173 146 36.41 ± 0.010 3641 
Benzyl Alcohol  230.66 ± 0.577 3295 426.08 ± 0.150 42600 
*= Solubility of drug in 1 ml of solvent divided by the solubility in 1ml of water, at 25°C 
 
Solubility of Artemisinin and Curcumin in selected 
binary co-solvent system  
 
The mixed solvent system composition, namely PEG 400–water 
(Smix 1), benzyl alcohol (BA)–water (Smix 2), PEG 400–ethanol 
(Smix 3),BA–ethanol (Smix 4),  and benzyl alcohol-PEG 400 (Smix 
5), were used for studying the solubility of Artemisinin and 
Curcumin depicted in Table 2. 
As the volume fraction of PEG 400 and benzyl alcohol (co-solvent) 
increased, in the binary mixture with water, the solubility of 
Artemisinin and Curcumin increased. However, it failed to achieve 
the desired solubility for Artemisinin (90 mg/ml) and Curcumin (180 
mg/ml) when the solvents ( PEG 400 or benzyl alcohol) were used 
in the permissible limits as per inactive ingredient guide. Hence, 
binary combination of PEG 400-water and benzyl alcohol-water 
cannot be considered for the formulation development. In PEG 
400-ethanol system, as the volume fraction of ethanol increased, 
solubility of Artemisinin and Curcumin decreased probably because 
of less polarity of ethanol as compared to PEG 400. As the volume 
fraction of PEG 400 increased, solubility of Artemisinin and 
Curcumin increased. But this enhancement also failed to achieve 
the desired solubility for Artemisinin and Curcumin. 
Solubility was also checked in the binary mixtures of benzyl alcohol 
and ethanol (Smix 4), and benzyl alcohol and PEG 400 (Smix 5). 
The solubility of Artemisinin and Curcumin was found to be higher 
in both of these solvent systems than other binary co-solvent 
systems. PEG 400 was able to dissolve more of the drugs. This 
may be due to favorable dielectric constant of PEG 400. The 
dielectric constant of PEG 400 is higher than that of ethanol. 
Hence, the solubility of Artemisinin and Curcumin was found to be 
higher in case of BA-PEG 400 co-solvent system. The 
enhancement in solubility also failed to achieve the desired 
solubility for Artemisinin and Curcumin by using the excipients in 
the permissible range. 
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Table 2: Solubility of Artemisinin and Curcumin in binary co-solvent system 
 
 
Ternary phase diagram 
 
Ternary co-solvent systems were prepared by using Tween 80 as a 
surfactant and binary co-solvent system of benzyl alcohol and PEG 
400. Addition of surfactant may enhance solubility of poorly soluble 
drug by micelle formation and also prevent precipitation of the 
solutes during dilution. Six ternary co-solvent systems were tested. 
Ternary phase diagram was constructed for a blend of benzyl 
alcohol, PEG 400 and Tween 80. The refractive index of the ternary 
solvent system was measured. Table 3 depicts composition of 
ternary solvent system and their refractive index. The values of the 
refractive index of different co-solvent system were nearer to the 
refractive index of water which depicts that given composition of 
solvents give the single phase system. Phase diagram and the 
miscibility region are shown in Figure 1. 
 
Table 3: Composition of ternary co-solvent system and their refractive index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Smix 1 
PEG 400 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
Water 0.9 0.8 0.7 0.6 0.4 0.5 0.3 0.2 0.1 
Solubility 
(mg/ml) 
 Artemisinin 0.40 ±0.00 2.06±0.115 3.22±0.017 3.72±0.011 4.32±0.0115 5.37±0.017 6.86±0.0175 7.70±0.005 8.22±0.0173 
Curcumin 0.63±0.461 2.81±0.011 4.51±0.01 9.22±0.017 12.32±0.005 18.32±0.023 24.20±0.011 29.62±0.01 33.22±0.017 
Smix 2 
BA 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
Water 0.9 0.8 0.7 0.6 0.4 0.5 0.3 0.2 0.1 
Solubility(mg/ml) Artemisinin 19.23±0.251 26.56±0.513 34.33±0.577 47.3±0.3 53.43±0.378 67.5±0.5 79.16±0.288 91.33±0.577 125.36±0.404 
 Curcumin 38.23±0.256 58.66±0.577 85.76±0.680 124.66±0.057 139.46±0.450 162.56±0.602 192.03±0.057 206.03±0.057 251.66±0.577 
Smix 3 
PEG 400 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
Ethanol 0.9 0.8 0.7 0.6 0.4 0.5 0.3 0.2 0.1 
Solubility 
(mg/ml) 
Artemisinin 2.81±0.01 3.56±0.005 5.20±0.005 6.22±0.005 7.22±0.01 8.30±0.017 10.22±0.017 12.32±0.0115 13.64±0.0057 
Curcumin 4.30±0.005 8.34±0.01 12.80±0.005 19.28±0.05 22.39±0.011 28.36±0.005 31.11±0 35.29±0.01 38.33±0.01 
Smix 4 
BA 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
Ethanol 0.9 0.8 0.7 0.6 0.4 0.5 0.3 0.2 0.1 
Solubility 
(mg/ml) 
Artemisinin 24.33±0.577 35.18±0.0519 49.58±0.0115 61.13±0.118 76.23±0.0288 91.19±0.182 109.41±0.156 130.86±0.005 142.99±0.591 
Curcumin 38.10±0.105 53.13±0.118 81.51±0.056 105.31±0.02 135.22±0.011 162.78±0.037 203.37±0.011 241.62±0.030 290.36±0.311 
Smix 5 
BA 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
PEG400 0.9 0.8 0.7 0.6 0.4 0.5 0.3 0.2 0.1 
Solubility 
(mg/ml) 
Artemisinin 32.35±0.304 52.23±0.028 71.33±0.032 96.12±0.023 114.28±0.052 136.31±0.01 161.57±0.496 193.16±0.144 209.20±0.080 
Curcumin 79.31±0.005 93.23±0.026 148.33±0.577 185.22±0.197 208.16±0.752 235.5±0.424 266.28±0.073 281.87±0.167 305.37±0.015 
Benzyl alcohol PEG 400 Tween 80 Refractive index 
0.10 0.90 0.50 1.32 
0.20 0.80 0.45 1.33 
0.30 0.70 0.45 1.32 
0.40 0.60 0.30 1.32 
0.50 0.50 0.30 1.31 
0.60 0.40 0.20 1.34 
0.70 0.30 0.25 1.33 
0.80 0.20 0.20 1.32 
0.90 0.10 0.10 1.33 
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Figure 1. Ternary phase diagram of benzyl alcohol, PEG 400 and Tween 80 
 
 
Development of parenteral injection 
 
On the basis of solubility data obtained from the ternary co-solvent 
system, formulation of aqueous injection of Artemisinin and 
Curcumin was prepared using the selected ternary co- solvent 
system. This formulation contained 90 mg of Artemisinin and 180 
mg of Curcumin in mixed solvent system (20% benzyl alcohol, 64% 
PEG 400 and 16% Tween 80). Other additives like 0.1% sodium 
bisulfate (antioxidant), 4% mannitol (osmogen) and water for 
injection quantity sufficient to prepare3 ml of parenteral injection. 
Drug–excipients compatibility studies 
 
UV spectral studies 
 
UV spectra of Artemisinin and Curcumin were recorded. The UV 
spectra of both drugs (depicted in Figure 2 and 3), show that there 
was no change in wavelength maxima of Artemisinin and Curcumin 
in the selected solvents. It can be inferred that both the drugs are 
compatible with the selected solvents. 
 
 
Figure 2.UV spectra’s of Artemisinin in different solvents A: UV spectra of Artemisinin in Benzyl alcohol, B: UV spectra of Artemisinin in PEG 400,  
C: UV spectra of Artemisinin in Binary mixture ofBA and PEG 400, D: UV spectra of Artemisinin in Ternary co-solvent 
Thakkar et al. International Journal of Drug Delivery 8 (3) 77-88 [2016] 
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Figure  3. UV spectra’s of  Curcumin in different solvents A: UV spectra of Curcumin in Benzyl alcohol, B:UV spectra of Curcumin in PEG 400, C: 
UV spectra of Curcumin in Binary mixture of BA and PEG 400, D: UV spectra of Curcumin in Ternary co-solvent 
 
FTIR study 
 
The possible interaction between Artemisinin, Curcumin and their 
mixture with co-solvent system (benzyl alcohol, PEG 400, and 
Tween 80) was examined by Infrared spectroscopy. The infrared  
spectra of drugs and drug co-solvent mixture are shown in Figure 
4. The IR spectra indicates compatibility between Artemisinin, 
Curcumin and co-solvent system. The spectra were compared with 
infrared spectrum of untreated drug. All the functional group 
frequencies were present. 
 
 
(A) 
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(B) 
 
(C) 
Figure  4.  FTIR Spectra’s of Artemisinin and Curcumin (CU) A: FTIR spectra of untreated Artemisinin, B: FTIR spectra of untreated Curcumin, C: 
Liquid FTIR spectra of final co-solvent system (ART+CU+BA+PEG 400 +Tween  80) 
 
Differential Scanning Calorimetric study 
 
DSC thermograms of Artemisinin, Curcumin and their mixture with 
co-solvent system are presented in Figure 5. The DSC thermogram 
of Artemisinin exhibited a single sharp exothermic peak at 155°C. 
Curcumin exhibited a single sharp endothermic peak at 180°C. 
Liquid DSC thermogram of the investigated co-solvent mixture 
exhibited the characteristic exothermic peak of Artemisinin at 155°C 
and endothermic peak of Curcumin at 180°C indicating the absence 
of interaction between the two drugs in the optimized co-solvent 
system. 
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(C) 
Figure  5. DSC thermogram of Artemisinin and Curcumin A: DSC thermo gram of Artemisinin, B: DSC thermo gram of Curcumin, C: Liquid DSC 
Thermo gram of final co-solvent system (AR+CU+BA+PEG 400+ Tween 80) 
 
 
Characterization of aqueous injection 
 
pH, clarity, viscosity, surface tension and specific 
gravity 
 
The pH of formulation was found to be 7.33± 0.0173, which is 
within acceptable range (pH 6.8 to 7.4). Hence, the formulation 
would not cause any irritation upon administration. Formulation was 
critically observed against black and white background which 
showed absence of particulate matters. Hence, clarity of 
formulation was found to be satisfactory. The mean viscosity of the 
optimized formulation was found to be 10.49centipoise. Viscosity of 
parenteral formulation is a very important criteria for inject ability 
and syringebility [23]. As the solution has less viscosity it has good 
syringebility and inject ability. The results of viscosity, surface 
tension and specific gravity are shown in Table 4. 
 
Table 4: Viscosity, Surface tension and Specific gravity of 
formulation  
Sample 
Viscosity 
(cp) 
Surface 
Tension(dyne/cm) 
Specific 
Gravity 
Water  0.8379 72.8 - 
Formulated 
injection 
10.55 59.9 1.4 
10.48 59.5 1.4 
10.46 58.7 1.4 
 
Drug content 
 
The drug content of Artemisinin and Curcumin was found to be 89.82 
mg/ml for Artemisinin i.e. 99.8 % and 179.94 mg/ml for Curcumin  i.e. 99.96 
%. 
 
Osmolarity 
 
Osmolarity of parenteral preparation should be in range of 285- 310 
mOsmol/L to avoid cellular damage. Osmolarity of the solution of 
the optimized formulation prepared using 4% mannitol was 297 
mOsmol/L, which is within acceptable range. 
 
Leaching/extraction test  
 
The effect of container on pH, viscosity and drug content of the 
formulation was measured. From the results,  it is concluded that 
glass vial, amber colored glass ampoule and flint glass ampoule 
had no significant effect on formulation characteristic as the pH of 
formulation remain unchanged which indicates absence of leaching 
of any alkali or acid material from containers. The drug content was 
unaltered. 
 
In-vitro erythrocyte toxicity study 
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The in vitro erythrocyte toxicity study was carried out to check 
safety of prepared parenteral formulation. Benzyl alcohol, PEG-
400, Tween 80 and optimized formulation showed considerably 
less than 10 % hemolytic activity which is consider as a safe and 
this formulation can be used parent rally.  
 
In-vitro anti-malarial assay 
 
In vitro anti-malarial assay showed the concentration which inhibits 
the complete maturation of ring stage parasites into schizonts. The 
minimum inhibitory concentration (MIC) was recorded. Quinine was 
used as the reference drug. The parenteral injection of Artemisinin 
and Curcumin was taken as test sample and MIC was recorded. 
The MIC of quinine and marketed combination of Artemether and 
Lumefantrine was also measured. The MIC of parenteral injection of 
Artemisinin and Curcumin was found to be 0.024 µg/ml, which is 
lower than the MIC of quinine (0.268µg/ml) and marketed 
formulation containing Artemether and Lumefantrine (0.033 µg/ml). 
It may be concluded that the prepared parenteral injection of 
Artemisinin and Curcumin is more efficacious than quinine and 
marketed formulation containing Artemether and Lumefantrine. 
 
Sterility test 
 
The optimized formulation showed clarity in both ATGM and SCDM 
media after 7 days. This results ensures sterility. 
 
Stability study 
 
Formulated aqueous injection was subjected to stability testing at 
5ºC±3ºC, at room temperature and at 40±2ºC/75±5% RH. Results 
of the stability study of formulation showed that it remains 
unchanged in respect of pH and color. Precipitate formation was  
not observed at different storage conditions, showing appreciable 
physical stability. Chemical stability was also noticed.  
 
 
 
 
Conclusion 
 
Binary solvent systems failed to give the required solubility of both 
the drugs. The ternary system comprising of benzyl alcohol, Tween 
80 and PEG 400 was more efficacious as compared to the binary 
system. Interaction was not observed between the drug and the 
excipients. The in vitro tests showed efficacy of the formulation. 
The aqueous injection containing the co-solvent system with 0.1 % 
sodium bisulfate, 4% mannitol and water for injection in sufficient 
quantity  to prepare 3 ml of aqueous injection may be considered 
as a promising formulation for malarial therapy.  
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